About International Stemcell Services
International Stemcell Services is a Healthcare company based in Bengaluru (India) founded in 2008. It provides storage of human adult stem cells. International Stemcell Services has raised $84.18 thousand across 1 funding round from investors including HCG. Its Indian entity Icrest Biotechnologies Limited reported revenue of ₹1.68 Cr. International Stemcell Services offers products and services including Stem Cell Banking, Cord Blood Banking, Cellular Therapy, and Platelet Rich Plasma (PRP). Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Services and Biorepository. Its competitors include LifeCell and Cordlife India; 1 of its 2 listed competitors has raised funding.
Company details
International Stemcell Services was founded in 2008 in Bengaluru, India, within the biotechnology sector focused on stem cell preservation. Stem cells are sourced from bone marrow, adipose tissue, umbilical cord blood, and dental pulp. These are processed and stored to support potential therapies for chronic conditions, including cancer. Operations emphasize secure, long-term cryopreservation services for medical applications.
- Headquarters Bengaluru, India
- SectorsHealthcare
- Phone•••• ••••
- Website internationalstemcellservices.com
- Social LinkedIn
- Legal Name Icrest Biotechnologies Limited
- Date of Incorporation 17 Sep, 2008
- Jurisdiction Bangalore, Karnataka, India
- Annual Revenue₹1.68 Cr
FY 2025 · +38% YoY
- Net Profit₹3 Lakh
FY 2025 · 2% margin
- EBITDA₹17.6 Lakh
FY 2025 · 10% margin
- Total Equity Funding$84.18K (USD)
in 1 rounds
- Latest Funding Round$84.18K (USD), Seed
May 2018
- Investors
Associated legal entities of International Stemcell Services
International Stemcell Services operates through Icrest Biotechnologies Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Icrest Biotechnologies Limited CIN U33100KA2008PLC047800 | Active | 17 Sep 2008 | Bangalore, Karnataka | ₹1.7 Cr | 5 | View details |
Products & Services of International Stemcell Services
International Stemcell Services offers a comprehensive portfolio of products and services, including Stem Cell Banking, Cord Blood Banking, Cellular Therapy, and Platelet Rich Plasma (PRP).
Secure storage of stem cells for future medical use and treatments.
Preserves umbilical cord blood for potential regenerative therapies.
Applies stem cells to treat conditions like cancer and vascular diseases.
Uses PRP for applications in hair loss and tissue regeneration.
Funding Insights of International Stemcell Services
International Stemcell Services has successfully raised a total of $84.18K through 1 strategic funding round. The most recent funding activity was a Seed round of $84.18 thousand completed in May 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $84,179
- Total Rounds 1
- Last Round Seed — $84,179
- First Round $84,179
(May 2018)
- Investors Count 1
All 1 funding rounds of International Stemcell Services with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2018 | $84,179 | Seed | – | HCG | – |
1 investors in total: 1 institutional.
Investors in International Stemcell Services
International Stemcell Services has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include HCG.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Chain of oncology hospitals | 1989 | hcgoncology.com | Bengaluru, India |
Investor details for International Stemcell Services
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Board of directors of Icrest Biotechnologies Limited (International Stemcell Services)
Icrest Biotechnologies Limited is the primary company behind International Stemcell Services. The board of Icrest Biotechnologies Limited currently have 5 directors; the longest-serving is Gopalakrishna Sreemushanam Anandarao, appointed in 2008. 5 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Gopalakrishna Sreemushanam Anandarao DIN 01197410 | Director | 17 Sep 2008 | 18 yrs 1 mo | Icrest Biotechnologies Limited |
| Jyothsna Ananda Rao DIN 01197460 | Whole-time director | 17 Sep 2008 | 18 yrs 1 mo | Icrest Biotechnologies Limited |
| Sunanda Ananda Rao DIN 01197386 | Director | 01 Mar 2010 | 16 yrs 8 mo | Icrest Biotechnologies Limited |
| Gururaj Ananda Rao DIN 01902753 | Managing Director | 01 Dec 2010 | 15 yrs 11 mo | Icrest Biotechnologies Limited |
| Basavalinga Ajaikumar Sadasivaiah DIN 00713779 | Director | 28 Feb 2024 | 2 yrs 8 mo | Icrest Biotechnologies Limited |
People of International Stemcell Services
1 people are tracked at International Stemcell Services (1 in leadership).
| Name | Role | Group |
|---|---|---|
| Managing Director | Leadership |
Complete people profiles for International Stemcell Services
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Financials of International Stemcell Services
Figures of Icrest Biotechnologies Limited, the primary company behind International Stemcell Services, for FY 2025. Revenue was ₹1.68 Cr (+38% year on year). Net profit was ₹3 Lakh (2% margin). EBITDA was ₹17.6 Lakh (10% margin). Revenue has grown at a compounded annual rate of +34% over three years and +4% over five years.
- ₹1.68 CrRevenue · FY 2025 · +38% YoY
- ₹3 LakhNet profit · 2% margin
- ₹17.6 LakhEBITDA · 10% margin
- ₹1.17 CrPaid-up capital
- +34%Revenue CAGR, 3 years
- +4%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Icrest Biotechnologies Limited are on its company page.
Detailed financial statements for International Stemcell Services
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of International Stemcell Services
2 dated milestones of International Stemcell Services across 10 years, from founding to its latest funding, stage changes and deals.
- Founded International Stemcell Services is founded.
- Funding First funding round of $84K.
Competitors of International Stemcell Services
International Stemcell Services has 2 listed competitors in our database, 1 of them funded. They include LifeCell and Cordlife India.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| lifecell.in | 2004 | Chennai, India | $61.21M | 1,188 | LifeCell is engaged in cord blood banking services. | |
| cordlifeindia.com | 2008 | Kolkata, India | 290 | Offers stem cell banking services for cord blood and cord lining storage globally. |
Detailed competitors of International Stemcell Services
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about International Stemcell Services
Complete news archive for International Stemcell Services
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about International Stemcell Services
International Stemcell Services was founded in 2008 and raised its 1st funding round 10 years after it was founded.
International Stemcell Services is headquartered in Bengaluru, India. It is registered at Bengaluru, Karnataka, India.
International Stemcell Services is a funded company, having raised a total of $84.18K across 1 funding round to date. The company's 1st funding round was a Seed of $84.18K, raised on May 2018.
The primary company behind International Stemcell Services, Icrest Biotechnologies Limited, reported revenue of ₹1.68 Cr for FY 2025, up 38% year on year.
International Stemcell Services was founded in 2008 in Bengaluru, India, within the biotechnology sector focused on stem cell preservation. Stem cells are sourced from bone marrow, adipose tissue, umbilical cord blood, and dental pulp. These are processed and stored to support potential therapies for chronic conditions, including cancer. Operations emphasize secure, long-term cryopreservation services for medical applications.
International Stemcell Services's top competitors include LifeCell and Cordlife India.
International Stemcell Services offers Stem Cell Banking, Cord Blood Banking, Cellular Therapy, and Platelet Rich Plasma (PRP).
International Stemcell Services has 1 investor. Key investors include HCG.
International Stemcell Services operates through Icrest Biotechnologies Limited.
The legal entities of International Stemcell Services currently have 5 directors, including Gururaj Ananda Rao, Gopalakrishna Sreemushanam Anandarao, Jyothsna Ananda Rao and others.